These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
239 related items for PubMed ID: 11239913
21. R+-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors. Nieri P, Martinotti E, Testai L, Adinolfi B, Calderone V, Breschi MC. Eur J Pharmacol; 2003 Jan 10; 459(1):75-81. PubMed ID: 12505536 [Abstract] [Full Text] [Related]
22. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor. Ruiu S, Pinna GA, Marchese G, Mussinu JM, Saba P, Tambaro S, Casti P, Vargiu R, Pani L. J Pharmacol Exp Ther; 2003 Jul 10; 306(1):363-70. PubMed ID: 12663689 [Abstract] [Full Text] [Related]
23. Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands. Smith SR, Terminelli C, Denhardt G. Eur J Pharmacol; 2001 Aug 03; 425(1):73-83. PubMed ID: 11672577 [Abstract] [Full Text] [Related]
24. In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding. Sim LJ, Selley DE, Childers SR. Proc Natl Acad Sci U S A; 1995 Aug 01; 92(16):7242-6. PubMed ID: 7638174 [Abstract] [Full Text] [Related]
25. Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTPgammaS binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamide. Romero J, Berrendero F, García-Gil L, Lin SY, Makriyannis A, Ramos JA, Fernández-Ruiz JJ. Neurochem Int; 1999 Jun 01; 34(6):473-82. PubMed ID: 10402222 [Abstract] [Full Text] [Related]
26. Cannabinoid receptor agonists inhibit Ca(2+) influx to synaptosomes from rat brain. Yoshihara S, Morimoto H, Ohori M, Yamada Y, Abe T, Arisaka O. Pharmacology; 2006 Jun 01; 76(4):157-62. PubMed ID: 16446560 [Abstract] [Full Text] [Related]
27. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. Smith SR, Terminelli C, Denhardt G. J Pharmacol Exp Ther; 2000 Apr 01; 293(1):136-50. PubMed ID: 10734163 [Abstract] [Full Text] [Related]
28. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol. McMahon LR. J Pharmacol Exp Ther; 2006 Dec 01; 319(3):1211-8. PubMed ID: 16943255 [Abstract] [Full Text] [Related]
30. Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo. Acquas E, Pisanu A, Marrocu P, Di Chiara G. Eur J Pharmacol; 2000 Aug 04; 401(2):179-85. PubMed ID: 10924924 [Abstract] [Full Text] [Related]
31. Status epilepticus causes a long-lasting redistribution of hippocampal cannabinoid type 1 receptor expression and function in the rat pilocarpine model of acquired epilepsy. Falenski KW, Blair RE, Sim-Selley LJ, Martin BR, DeLorenzo RJ. Neuroscience; 2007 May 25; 146(3):1232-44. PubMed ID: 17433556 [Abstract] [Full Text] [Related]
32. Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim-Selley LJ. J Neurochem; 1999 Dec 25; 73(6):2447-59. PubMed ID: 10582605 [Abstract] [Full Text] [Related]
33. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. Griffin G, Atkinson PJ, Showalter VM, Martin BR, Abood ME. J Pharmacol Exp Ther; 1998 May 25; 285(2):553-60. PubMed ID: 9580597 [Abstract] [Full Text] [Related]
34. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Breivogel CS, Griffin G, Di Marzo V, Martin BR. Mol Pharmacol; 2001 Jul 25; 60(1):155-63. PubMed ID: 11408610 [Abstract] [Full Text] [Related]
35. Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. Tyler K, Hillard CJ, Greenwood-Van Meerveld B. Eur J Pharmacol; 2000 Dec 08; 409(2):207-11. PubMed ID: 11104836 [Abstract] [Full Text] [Related]
36. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells. McCollum L, Howlett AC, Mukhopadhyay S. J Pharmacol Exp Ther; 2007 Jun 08; 321(3):930-7. PubMed ID: 17379772 [Abstract] [Full Text] [Related]
37. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Terranova JP, Michaud JC, Le Fur G, Soubrié P. Naunyn Schmiedebergs Arch Pharmacol; 1995 Nov 08; 352(5):576-9. PubMed ID: 8751088 [Abstract] [Full Text] [Related]
38. Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux. Cui YY, D'Agostino B, Risse PA, Marrocco G, Naline E, Zhang Y, Chen HZ, Finance O, Rinaldi-Carmona M, Rossi F, Advenier C. Eur J Pharmacol; 2007 Nov 14; 573(1-3):206-13. PubMed ID: 17643417 [Abstract] [Full Text] [Related]
40. Characterization of cannabinoid modulation of sensory neurotransmission in the rat isolated mesenteric arterial bed. Duncan M, Kendall DA, Ralevic V. J Pharmacol Exp Ther; 2004 Oct 26; 311(1):411-9. PubMed ID: 15205450 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]